Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition. (2019)

First Author: Brumpton BM
Attributed to:  Mendelian randomization to hypothesis-free causal inference funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1161/circgen.118.002335

PubMed Identifier: 30645169

Publication URI: http://europepmc.org/abstract/MED/30645169

Type: Journal Article/Review

Volume: 12

Parent Publication: Circulation. Genomic and precision medicine

Issue: 1

ISSN: 2574-8300